# Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab

> **NCT02157181** · PHASE2 · COMPLETED · sponsor: **Jurgen Barth** · enrollment: 89 (actual)

## Conditions studied

- Hairy Cell Leukemia (HCL)

## Interventions

- **DRUG:** 2CdA +/- Rituximab

## Key facts

- **NCT ID:** NCT02157181
- **Lead sponsor:** Jurgen Barth
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2012-09
- **Final completion:** 2013-01
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2024-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02157181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02157181, "Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02157181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*